Volume 19, Number 10—October 2013
Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era
Highlight and copy the desired format.
|EID||Wikswo ME, Desai R, Edwards KM, Staat M, Szilagyi PG, Weinberg GA, et al. Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era. Emerg Infect Dis. 2013;19(10):1691-1693. https://dx.doi.org/10.3201/eid1910.130448|
|AMA||Wikswo ME, Desai R, Edwards KM, et al. Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era. Emerging Infectious Diseases. 2013;19(10):1691-1693. doi:10.3201/eid1910.130448.|
|APA||Wikswo, M. E., Desai, R., Edwards, K. M., Staat, M., Szilagyi, P. G., Weinberg, G. A....Hall, A. J. (2013). Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era. Emerging Infectious Diseases, 19(10), 1691-1693. https://dx.doi.org/10.3201/eid1910.130448.|
To the Editor: After the substantial decrease in acute gastroenteritis (AGE) in children caused by rotavirus after introduction of 2 rotavirus vaccines (1), norovirus has become the leading cause of medically attended AGE in US children <5 years of age (2). We describe the clinical characteristics of norovirus disease and assessed whether rotavirus vaccine protected against norovirus AGE.
During October 2008–September 2010, the New Vaccine Surveillance Network enrolled 1,897 children <5 years of age with symptoms of AGE (≥3 episodes of diarrhea or any episodes of vomiting within 24 hours lasting ≤10 days) who came to hospitals, emergency departments, and outpatient clinics in Cincinnati, Ohio; Nashville, Tennessee; and Rochester, New York, USA, as described (2).
Epidemiologic, clinical, and vaccination data were systematically collected. Whole fecal specimens were obtained within 14 days of the date of visit and tested for rotavirus by using a commercial enzyme immunoassay (Rotaclone; Meridian Bioscience, Inc., Cincinnati, OH, USA) and for norovirus by using real-time reverse transcription quantitative PCR, followed by sequence analysis of positive samples (3,4). Clinical severity was assessed by using a 20-point scoring system (5), which was modified to use behavior as a proxy for dehydration. Odds ratios used to calculate vaccine effectiveness (VE) were adjusted for race and insurance status (online Technical Appendix, wwwnc.cdc.gov/EID/article/19/10/13-0448-Techapp1.pdf [PDF - 297 KB - 6 pages]).
Inclusion criteria for this study corresponded with criteria used in previous New Vaccine Surveillance Network studies (2,6). Children were age eligible for pentavalent rotavirus vaccination (RV5), had a fecal specimen tested for norovirus and rotavirus, and had complete vaccination and AGE symptom information (Technical Appendix Figure 1 [PDF - 297 KB - 6 pages]). Children who received a dose of monovalent rotavirus vaccine or vaccine of unknown type or were positive for rotavirus and norovirus were excluded from analyses. Only unvaccinated rotavirus-positive children (n = 69, 72%) were used in severity score analyses because RV5 is known to attenuate rotavirus illness (6).
Of the enrolled children, 574 met the inclusion criteria; 144 (25%) norovirus-positive case-patients, 96 (17%) rotavirus-positive case-patients, and 334 (58%) patients negative for norovirus and rotavirus (control patients with AGE) (Technical Appendix Figure 1 [PDF - 297 KB - 6 pages]). Of 144 norovirus-positive specimens, 10 (7%) could not be genotyped, 4 (3%) were positive for genogroup (G) I, and 130 (90%) were positive for GII. The most common genotype was GII.4 Minerva (74 [51%]).
Norovirus case-patients were significantly more likely than control patients with AGE to have longer duration and more episodes of vomiting in a 24-hour period (p = 0.003 and p<0.0001, respectively) but were significantly less likely to report fever (p = 0.001) (Table). However, the median severity score for norovirus case-patients did not differ from that for control patients with AGE (11 vs. 10, respectively). Individual severity score components and overall severity scores did not differ among case-patients infected with norovirus who received 0, 1 or 2, or 3 doses of RV5, but the duration of vomiting was longer in case-patients infected with norovirus GII.4 than in those infected with a non-GII.4 genotype (Technical Appendix Tables 1, 2; Figure 2 [PDF - 297 KB - 6 pages]).
Relative to the 69 unvaccinated rotavirus case-patients, norovirus case-patients had shorter duration and fewer episodes of diarrhea in a 24-hour period (p = 0.003 and p = 0.0003, respectively). Norovirus case-patients were also significantly less likely to be hospitalized (p = 0.02), have fever (p<0.0001), and have severe behavior changes (p<0.0001); they also had lower overall severity scores (p<0.0001) than unvaccinated rotavirus case-patients.
Compared with control patients with AGE, VE of any dose of RV5 against norovirus disease was −0.9% (95% CI −55% to 34%). A full course of RV5 likewise showed no evidence of protection against norovirus (VE 5%; 95% CI −50% to 40%), and results were consistent across age groups.
In conclusion, we found that norovirus AGE was associated with more frequent and prolonged vomiting but less fever than AGE not caused by norovirus or rotavirus. Case-patients infected with norovirus GII.4 also had a longer duration of vomiting than did case-patients infected with non-GII.4 norovirus genotypes. However, AGE among unvaccinated rotavirus case-patients was more severe than among norovirus case-patients, and was characterized by higher fever and more frequent and severe diarrhea. This finding confirms findings in a study of children in Finland (7), although our study found no difference in frequency or severity of vomiting between patients with rotavirus disease or those with norovirus disease.
In addition, vaccination against rotavirus did not provide protection against norovirus and had no effect on the clinical course of norovirus disease, which is consistent with other findings (8). Although an earlier rotavirus vaccine, which has subsequently been withdrawn, may have provided some nonspecific protection by reducing intensity and duration of diarrhea associated with adenovirus and sapovirus (9,10), our study did not demonstrate a similar effect on norovirus-associated diarrhea after vaccination with RV5. This study reinforces the hypothesis that norovirus can cause severe AGE among young children and should be considered as a specific target for vaccine development.
- Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, Esposito DH, Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J. 2011;30(Suppl):S56–60 .
- Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med. 2013;368:1121–30 .
- Trujillo AA, McCaustland KA, Zheng DP, Hadley LA, Vaughn G, Adams SM, Use of TaqMan real-time reverse transcription–PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol. 2006;44:1405–12 .
- Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis. 2011;17:1389–95 .
- Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259–67.
- Staat MA, Payne DC, Donauer S, Weinberg GA, Edwards KM, Szilagyi PG, Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128:e267–75 .
- Pang XL, Joensuu J, Vesikari T. Human calicivirus-associated sporadic gastroenteritis in Finnish children less than two years of age followed prospectively during a rotavirus vaccine trial. Pediatr Infect Dis J. 1999;18:420–6.
- Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Karvonen A, Vesikari T. Norovirus gastroenteritis in young children receiving human rotavirus vaccine. Scand J Infect Dis. 2010;42:540–4.
- Pang XL, Zeng SQ, Honma S, Nakata S, Vesikari T. Effect of rotavirus vaccine on Sapporo virus gastroenteritis in Finnish infants. Pediatr Infect Dis J. 2001;20:295–300.
- Pang XL, Koskenniemi E, Joensuu J, Vesikari T. Effect of rhesus rotavirus vaccine on enteric adenovirus–associated diarrhea in children. J Pediatr Gastroenterol Nutr. 1999;29:366–9 .
- Table. Clinical profile and severity score of norovirus case-patients compared with acute gastroenteritis control patients and unvaccinated rotavirus case-patients, New Vaccine Surveillance Network, United States, 2008–2010
- Technical Appendix. . Detailed information on clinical profile of children with norovirus disease in rotavirus vaccine era. 297 KB
Please use the form below to submit correspondence to the authors or contact them at the following address:
Mary E. Wikswo, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A34, Atlanta, GA 30333, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: September 16, 2013
- Page last updated: September 16, 2013
- Page last reviewed: September 16, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)